StockData

Autolus Therapeutics vs Iovance Biotherapeutics

AUTL and IOVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AUTL and IOVA compare

Iovance Biotherapeutics is the larger company, worth 11 times as much as Autolus Therapeutics ($3.4B against $303M).

Autolus Therapeutics grew revenue faster over the last twelve months (292% versus 34.5% for Iovance Biotherapeutics).

Iovance Biotherapeutics keeps more of each dollar of sales as profit, with a net margin of −89.1% compared with −239% at Autolus Therapeutics.

Iovance Biotherapeutics scores higher on the StockData Score (9 against 5 for Autolus Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAUTLIOVA
Size and price
Market cap$303M$3.4B
Share price$1.14$7.55
Change, 1 year−10.9%213%
Change, 5 years−81.8%−59.2%
Beta (5Y)3.401.45
Employees754975
StockData Score
Total score59 (better)
Valuation score1 (better)0
Growth score3 (better)2
Performance score01 (better)
Health score16 (better)
Dividend score00
Valuation
P/S2.6× (better)10.5×
P/B4.1× (better)4.6×
FCF yield−76.7%−8.7% (better)
Fair value$1.41$4.06
Margin of safety19.3% (better)−86.1%
Growth
Revenue growth (TTM)292% (better)34.5%
Profitability
Gross margin15.7%48.4% (better)
Operating margin−211%−92.7% (better)
Net margin−239%−89.1% (better)
FCF margin−198%−91.2% (better)
Return on equity−133%−40.4% (better)
Return on invested capital–−57.0%
Financial health
Debt / equity–0.00
Interest coverage−5.9×–
Current ratio4.89 (better)4.35
Altman Z-score−4.586.73 (better)
Piotroski F-score24 (better)
Dividends and buybacks
Buyback yield–−8.5%
Shareholder yield0.00% (better)−8.5%
Ownership
Held by institutions49.7%63.3%
Held by insiders24.6%0.39%
Insider net buying, 12 months−$15.7K–
Short interest, % of float–14.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.